Onsdag 30 Oktober | 09:27:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-20 08:00 Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-20 - X-dag ordinarie utdelning MODTX 0.00 SEK
2024-05-17 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-16 - Kvartalsrapport 2022-Q1
2022-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2022-05-11 - Årsstämma
2022-02-22 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Modus Therapeutics är verksamt inom bioteknik. Produktportföljen är bred och inkluderar exempelvis sevuparin. Bolagets fokus är att utveckla sevuparin för patienter med sepsis / septisk chock, ett allvarligt och ofta dödligt tillstånd. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten med tillhörande forskning drivs med störst närvaro inom Sverige.
2023-08-23 08:00:00

STOCKHOLM, SWEDEN - 23 August 2023: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the second quarter 2023. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.

John Öhd, Modus Therapeutics' CEO, commented: ”The second quarter of 2023 was very productive for Modus and saw us make great progress in delivering on the broad clinical potential of sevuparin. We have continued to move forward with the planned clinical development of sevuparin for the treatment of sepsis, based on the positive initial clinical data that we have generated. In parallel, we have produced a compelling data set that highlights sevuparin’s potential in a new, and large opportunity, anemia related to chronic inflammation and kidney disease. This progress means we have significantly increased the potential value that we could generate from sevuparin while at the same time giving us greater control and optionality in how we develop the business. The next 12 months promise to be an exciting time for Modus Therapeutics, and I am looking forward to the future with great confidence.”

The second quarter in figures

  • The loss after tax amounted to TSEK 4 695 (2 992).
  • The loss per share amounted to SEK 0,29 (0,19).
  • The cash flow from current operations was negative in the amount of TSEK 4 267 (3 228).

The first half-year in figures

  • The loss after tax amounted to TSEK 10 735 (6 057).
  • The loss per share amounted to SEK 0,67 (0,38).
  • The cash flow from current operations was negative in the amount of TSEK 10 602 (10 773).

Important events during the second quarter

  • Modus Therapeutics participated in LSX, London.
  • The annual general meeting was held on May 11.
  • Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic inflammation and kidney disease at the annual European Hematology Association Congress.

Important events after the end of the period

No events to report.

CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid today August 23 at 14:00 Link to Interview: https://www.youtube.com/watch?v=EqOVbiRP5iY